Delivery Order SPE2DB22D3501-SPE2DB26FTG15
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,221.17 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with performance in Conshohocken, Pennsylvania. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of July 29, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $1 billion and extends...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $34,507.05 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 3, 2025. This competitively awarded, firm fixed-price delivery order was issued under a non-set-aside procurement and represents a single transaction for pharmaceutical supply to support federal medical needs. The place of performance is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $31,701.45 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injectors. This competitively awarded, firm fixed-price contract was issued on September 12, 2025, with an ultimate completion date of September 15, 2025. The pharmaceutical products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $37,706.24 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with a completion date of September 4, 2025. This firm fixed-price delivery order represents a non-competitive award, as no set-aside designation was applied. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs across military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/mL SureClick auto-injectors. This competitively awarded, firm fixed-price delivery order was issued on July 29, 2025, with an ultimate completion date of July 30, 2025, and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,061.39 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injectors. The contract, awarded on October 27, 2025, represents a firm fixed-price delivery order with an ultimate completion date of October 28, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. This non-set-aside award was competitively awarded to AmerisourceBergen, a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $10,594.36 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injectors. The contract, issued on September 25, 2025, with an ultimate completion date of September 26, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is issued under the company's larger...
- The Defense Logistics Agency awarded a $27,880.54 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 5, 2025. This non-competitive delivery order represents a firm fixed-price purchase under the company's existing contract vehicle with DLA. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of June 23, 2025. This is a firm fixed price delivery order with no set-aside designation, representing a competitive award to the pharmaceutical distributor's Conshohocken, Pennsylvania location. The contract falls under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,068.89 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injectors. This is a firm fixed-price delivery order with no set-aside designation, awarded on October 15, 2025, with an ultimate completion date of October 16, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB26FTG15Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,246.73 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/mL SureClick auto-injectors. This competitively awarded, firm fixed-price delivery order was issued on October 27, 2025, with an ultimate completion date of October 28, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract under a larger vehicle, this delivery order leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, a comprehensive global pharmaceutical support agreement valued at $999,999,999.00 and running through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement across the Defense Health Agency and military healthcare systems. Repatha (evolocumab) is a PCSK9 inhibitor prescribed for managing high cholesterol in patients with cardiovascular disease risk. Through its prime IDC with DLA, AmerisourceBergen maintains authority to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company's federal contract portfolio demonstrates consistent performance delivering specialty medications, vaccines, and medical devices across multiple therapeutic domains through competitively awarded delivery orders with firm fixed pricing.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 10/27/25 |